Molecular investigations of antithrombin instability and heparin binding mechanism

抗凝血酶不稳定性和肝素结合机制的分子研究

• 批准号: nhmrc : 124301
• 负责人: Prof Robert Pike
• 金额: $ 13.05万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2000
• 资助国家: 澳大利亚
• 起止时间: 2000-01-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/molecular-investigations-antithrombin-binding-mechanism/97864
• 关键词: Molecular; investigations; antithrombin; instability; heparin

Thrombosis is a significant disease affecting a large number of people. The primary treatment for episodes of acute thrombosis is administration of the anticoagulant, heparin. The effector molecule through which heparin carries out its action is the serine proteinase inhibitor, antithrombin. This molecule regulates blood clotting by inhibiting the proteinases which carry out this process. Antithrombin is converted from a poor inhibitor of coagulation proteases to a very good inhibitor on binding heparin. This provides a control point for coagulation. The mechanism by which antithrombin is converted to a very good inhibitor of coagulation proteases involves a large change in the structure of this protein. These changes in structure are linked to the changes which occur when antithrombin becomes inactive through the process of polymerisation. Certain patients with thrombosis have been found to have changes in both the stability and heparin affinity of their antithrombin molecules, which forms the underlying basis for the disease. We wish to study the reasons for the effects of mutations in the antithrombin variants by making recombinant mutants which mimic the molecules in the thrombotic patients and carrying out detailed, sophisticated molecular analyses of their interaction with heparin and proteases and their stability under various conditions. Additionally we will engineer recombinant mutants of antithrombin which we believe will stabilise the molecule and potentially act as an improved supplement for therapy. This analysis will provide important insights into the functioning of both heparin and antithrombin and thereby significantly improve our understanding of the control of coagulation.

血栓形成是一种影响大量人群的重要疾病。急性血栓形成发作的主要治疗是给予抗凝剂肝素。肝素发挥作用的效应分子是丝氨酸蛋白酶抑制剂，即抗凝血酶。这种分子通过抑制蛋白酶来调节血液凝固。抗凝血酶从凝血蛋白酶的不良抑制剂转化为结合肝素的非常好的抑制剂。这为凝固提供了控制点。抗凝血酶转化为凝血蛋白酶的非常好的抑制剂的机制涉及这种蛋白质结构的大的变化。这些结构变化与抗凝血酶通过聚合过程变得无活性时发生的变化有关。已经发现某些患有血栓形成的患者的抗凝血酶分子的稳定性和肝素亲和力都发生了变化，这形成了疾病的潜在基础。我们希望研究抗凝血酶变异体中突变效应的原因，方法是制造重组突变体，模拟血栓形成患者中的分子，并对其与肝素和蛋白酶的相互作用及其在各种条件下的稳定性进行详细、复杂的分子分析。此外，我们将工程抗凝血酶的重组突变体，我们相信这将稳定分子，并有可能作为一个改进的补充治疗。这项分析将为肝素和抗凝血酶的功能提供重要的见解，从而显着提高我们对凝血控制的理解。